NCT06360588 2026-04-17
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT06126276 2026-04-16
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06351371 2026-04-14
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06009926 2026-04-13
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06136897 2026-04-13
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06827054 2026-03-24
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
NCT05504291 2026-02-17
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Children's Oncology Group
Phase 2 Recruiting
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05715281 2025-11-25
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting